Science & Technology

With an eye on innovation™

we deliver first-in-class solutions and technologies to provide a brighter future for those at risk of losing their sight. EyePoint specializes in the development of sustained-release drug delivery to treat debilitating diseases of the eye and other localized, chronic conditions.

Vorolanib - Selective and Potent Pan-VEGF Receptor Inhibitor

Composition of matter patent into 2037
Previous Phase 1 and Phase 2 clinical trials in wet AMD as an oral therapy showed compelling efficacy data with no ocular toxicity observed^1,2
In-vivo studies demonstrate encouraging neuroprotection data and potential anti-fibrosis effect³
Reduced off-target binding of receptors associated with systemic side effects of kinase inhibitors (TKIs)

Vorolanib inhibits pathways with key roles in angiogenesis and pathological vascular leakage
- Potent and selective pan–VEGF receptor inhibitor
- Does not inhibit TIE2 receptors at clinically relevant doses
Acts intracellularly and inhibits proangiogenic signaling

DURASERT^®

Safe Sustained IVT Drug Delivery

Used in four of six FDA approved intravitreal sustained delivery products
Delivered by a single in-office IVT injection
Continuous, stable release of drug with zero-order kinetics

Durasert E™: bioerodible

Non-erodible polyimide coating removed
Bioerodible matrix is designed to deplete drug load before fully eroding

Durasert^®: non-erodible

YUTIQ^® (Alimera)
ILUVIEN^® (Alimera)
RETISERT^® (B&L)
VITRASERT^® (B&L)

VERISOME^® TECHNOLOGY

Verisome® technology is a novel, sustained-delivery platform

Highlights:

Biodegradable liquid in aqueous sphere
Customizable duration from one week to several months

DEXYCU^®

DEXYCU is approved for the treatment of inflammation following ocular surgery.

Partnerships and BD Initiatives

EyePoint technologies have broad applicability across many therapeutic areas. Our validated technologies can be utilized to deliver new drugs or to repurpose existing molecules in new applications. EyePoint seeks additional strategic partners to collaborate on the development of new sustained-release drug suspensions and inserts, to access complementary research, and to expand our product portfolio.

References: 1. Jackson et al. JAMA Ophthalmol 2017. 2. Cohen MN et al. Br J Ophthalmol. 2021. 3. ARVO 2023 Presentation.

Science & Technology

Vorolanib - Selective and Potent Pan-VEGF Receptor Inhibitor

DURASERT®